**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 69397

**Manuscript Type:** LETTER TO THE EDITOR

**Gastrointestinal symptoms in patients with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2?**

Ribeiro IB *et al*. Gastrointestinal symptoms in patients with COVID-19

Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Eduardo Guimarães Hourneaux de Moura

**Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Eduardo Guimarães Hourneaux de Moura,** Departamento de Gastroenterologia, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 05403-010, Brazil

**Author contributions:** Ribeiro IB conceptualized the study and wrote the manuscript; de Moura DTH and de Moura EGH performed the critical final review of manuscript.

**Corresponding author: Igor Braga Ribeiro, MD, Associate Research Scientist, Surgeon,** Departamento de Gastroenterologia, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr Enéas de Carvalho Aguiar, 225, 6o andar, bloco 3, Sao Paulo 05403-010, Brazil. igorbraga1@gmail.com

**Received:** June 29, 2021

**Revised:** July 14, 2021

**Accepted:** August 25, 2021

**Published online:** October 7, 2021

**Abstract**

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although, respiratory symptoms are typical the digestive system is also a susceptible target with gastrointestinal symptoms present even in the absence of respiratory symptoms. The gastrointestinal symptoms of COVID-19 include diarrhea, abdominal pain, anorexia, and nausea among other symptoms. Some questions that remain to be answered include: Do patients with gastrointestinal symptoms have a higher mortality? SARS-CoV-2 variants are already a global reality: Do these variants present with a greater prevalence of gastrointestinal symptoms? Do patients with these symptoms warrant more intensive care unit care?

**Key Words:** COVID-19; SARS-CoV-2; Gastrointestinal symptoms; Intensive care unit; Variant

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Ribeiro IB, de Moura DTH, de Moura EGH. Gastrointestinal symptoms in patients with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2? *World J Gastroenterol* 2021; 27(37): 6345-6347

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i37/6345.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i37.6345

**Core Tip:** With the emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its clinical manifestations, the following questions have arisen: are gastrointestinal symptoms and complications the same as the other variants or are they different? And are these related to severity of the disease? In this letter to the editor, we discuss the relationship between the new SARS-CoV-2 variants with gastrointestinal manifestations and the severity of disease with the new variants.

**TO THE EDITOR**

We read with interest the article by Cao *et al*[1] titled “Coronavirus disease 2019 (COVID-19) and its effects on the digestive system.”

In 2020, our team conducted a cohort study[2] evaluating 400 patients diagnosed with COVID-19 that, even though it is the largest study in Latin America, unfortunately, was not included in the author’s review. In our study, 33.25% of patients reported one or more gastrointestinal symptoms, with diarrhea being the most common, representing approximately 17% of the total. This data corroborates the author’s review. It was also found that when these patients had gastrointestinal symptoms, they had a greater tendency to have other concomitant symptoms, especially myalgia and fatigue (*P* < 0.05).

It was also observed that patients with chronic kidney disease (*P* < 0.05), using chronic immunosuppressants, or chronic use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitors had a higher prevalence of gastrointestinal symptoms. Admission to the intensive care unit (ICU), need for mechanical ventilation, length of stay in the ICU, length of hospital stay, need for vasopressor support, laboratory results, and hospital mortality did not differ based on the presence of gastrointestinal symptoms (*P* > 0.05). Regression analyzes showed that immunosuppression [odds ratio (OR): 2.60 (95% confidence interval (CI): 1.20-5.63)], male sex [OR: 1.94 (95%CI: 1.12-3.36)], and older age [OR: 1.04 (95%CI: 1.02-1.06)] were associated with increased mortality.

As described above, our study[2] demonstrated, before the emergence of the new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[3,4], that gastrointestinal symptoms were not associated with a greater need for ICU admission or the severity of the disease in patients in Latin America.

This is a very controversial topic; some studies suggest a less severe clinical evolution in patients with gastrointestinal symptoms[5,6], whereas in the study by Redd *et al*[7], there was no statistical difference.

The study by Leal *et al*[8], evaluating 234 European patients with digestive symptoms, also had a more favorable and non-severe prognosis.

In a review carried out by Wang *et al*[9], it was observed that pancreatic damage or mesenteric ischemia/thrombosis could increase mortality.

In the pediatric population, in the study by de Paula *et al*[10], logistic regression analysis identified that laboratory-confirmed COVID-19 pediatric patients with gastrointestinal symptoms had an increased risk of cardiac abnormalities confirmed by echocardiogram (OR: 6316; 95%CI: 1.717-79043; *P* = 0.012).

We emphasize that in all these studies there was no distinction regarding the variety of SARS-CoV-2 studied.

It is currently known that the high expression of angiotensin-converting enzyme 2 in the lung and the intestinal tract makes the small bowel and colon highly susceptible to SARS-CoV-2 infection, which offers a potential explanation for diarrhea observed in many COVID-19 patients. Since tryptophan absorption requires angiotensin-converting enzyme 2, its deficiency can alter the intestinal microbiota and cause intestinal inflammation[11].

Given the above, we believe a more realistic discussion to be made, and we ask the authors the following: (1) Do patients with gastrointestinal symptoms have more severe disease outcomes or not? (2) Do SARS-CoV-2 variants have a greater gastrointestinal involvement? (3) Do SARS-CoV-2 variants have a relationship between gastrointestinal symptoms and/or disease severity? and (4) Do these patients have a greater need for admission to ICUs?

Finally, we would like to congratulate and thank the authors on the level of shared evidence.

**Acknowledgments**

We would like to thank Dr. Sergio A. Sánchez-Luna for reviewing the English translation of this article.

**REFERENCES**

1 **Cao TT**, Zhang GQ, Pellegrini E, Zhao Q, Li J, Luo LJ, Pan HQ. COVID-19 and its effects on the digestive system. *World J Gastroenterol* 2021; **27**: 3502-3515 [PMID: 34239265 DOI: 10.3748/wjg.v27.i24.3502]

2 **Moura DTH**, Proença IM, McCarty TR, Sagae VMT, Ribeiro IB, Oliveira GHP, Souza GMV, Hirsch BS, Scatimburgo MVCV, Thompson CC, Carrilho FJ, Cecconello I, Moura EGH. Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital. *Clinics (Sao Paulo)* 2020; **75**: e2271 [PMID: 33146362 DOI: 10.6061/clinics/2020/e2271]

3 **SeyedAlinaghi S**, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, Soleymanzadeh M, Barzegary A, Afsahi AM, Vahedi F, Shamsabadi A, Behnezhad F, Saeidi S, Mehraeen E, Shayesteh Jahanfar. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. *Eur J Med Res* 2021; **26**: 51 [PMID: 34103090 DOI: 10.1186/s40001-021-00524-8]

4 **Harvey WT**, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A; COVID-19 Genomics UK (COG-UK) Consortium, Peacock SJ, Robertson DL. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021; **19**: 409-424 [PMID: 34075212 DOI: 10.1038/s41579-021-00573-0]

5 **Mao R**, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 667-678 [PMID: 32405603 DOI: 10.1016/S2468-1253(20)30126-6]

6 **Aghemo A**, Piovani D, Parigi TL, Brunetta E, Pugliese N, Vespa E, Omodei PD, Preatoni P, Lleo A, Repici A, Voza A, Cecconi M, Malesci A, Bonovas S, Danese S; Humanitas COVID-19 Task Force. COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. *Clin Gastroenterol Hepatol* 2020; **18**: 2366-2368.e3 [PMID: 32437870 DOI: 10.1016/j.cgh.2020.05.011]

7 **Redd WD**, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC, Shen L, Chan WW. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. *Gastroenterology* 2020; **159**: 765-767.e2 [PMID: 32333911 DOI: 10.1053/j.gastro.2020.04.045]

8 **Leal T**, Costa E, Arroja B, Gonçalves R, Alves J. Gastrointestinal manifestations of COVID-19: results from a European centre. *Eur J Gastroenterol Hepatol* 2021; **33**: 691-694 [PMID: 33787540 DOI: 10.1097/MEG.0000000000002152]

9 **Wang MK**, Yue HY, Cai J, Zhai YJ, Peng JH, Hui JF, Hou DY, Li WP, Yang JS. COVID-19 and the digestive system: A comprehensive review. *World J Clin Cases* 2021; **9**: 3796-3813 [PMID: 34141737 DOI: 10.12998/wjcc.v9.i16.3796]

10 **de Paula CSY**, Palandri GG, Fonseca TS, Vendramini TCA, Farhat SCL, Pereira MFB, Litvinov N, Toma RK, de Sá FVM, Rodrigues KR, Schvartsman C, Forsait S, Sakita NK, Kanunfre KA, Rocha MC, Dos Santos EH, Okay TS, Pinho JRR, de Carvalho WB, Carneiro-Sampaio M, Almeida Silva CA, Marques HHS; Pediatric COVID HC-FMUSP Study Group. Gastrointestinal manifestations are associated with severe pediatric COVID-19: A study in tertiary hospital. *J Infect* 2021; **83**: e22-e25 [PMID: 33940088 DOI: 10.1016/j.jinf.2021.04.030]

11 **Ma C**, Cong Y, Zhang H. COVID-19 and the Digestive System. *Am J Gastroenterol* 2020; **115**: 1003-1006 [PMID: 32618648 DOI: 10.14309/ajg.0000000000000691]

**Footnotes**

**Conflict-of-interest statement:** There is nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** June 29, 2021

**First decision:** July 13, 2021

**Article in press:** August 25, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Kumar A, Zhang H **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Li X



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**